Pricing Log in Create free account

CNS Pharmaceuticals, Inc. (CNSP) vs Longeveron Inc. (LGVN)

CNS Pharmaceuticals, Inc. and Longeveron Inc. are both Biotechnology companies. CNS Pharmaceuticals, Inc. and Longeveron Inc. are of similar size ($5.9M and $5.5M). CNS Pharmaceuticals, Inc. has the higher net margin (0.00% vs −1,977.6%) and the higher return on invested capital (0.00% vs −4,549.0%). Across the 13 metrics below, CNS Pharmaceuticals, Inc. leads on 9 and Longeveron Inc. on 4.

Valuation

Metric CNSP LGVN Biotechnology median
P/E n/m n/m 10.60
P/S n/m 4.73 9.40
P/B 1.46 0.54 2.13
Price to free cash flow n/m n/m 25.18
EV/EBITDA n/m 0.16 0.66
EV/Sales n/m (3.10) 9.02
Earnings yield (606.43%) (568.59%) (32.88%)
Free cash flow yield (50.55%) (371.04%) (23.13%)

Profitability

Metric CNSP LGVN Biotechnology median
Gross margin 0.00% 69.76% 68.51%
Operating margin 0.00% (1,992.84%) 0.00%
Net margin 0.00% (1,977.59%) 0.00%
Free cash flow margin 0.00% (1,755.69%) 0.00%
Return on equity (106.62%) (203.61%) (51.96%)
Return on assets (91.64%) (145.64%) (46.06%)
Return on invested capital 0.00% (4,549.04%) 0.00%

Growth

Metric CNSP LGVN Biotechnology median
Revenue growth (TTM) — (42.74%) 6.76%
EPS growth (last fiscal year) 92.34% 50.76% 29.88%
Revenue growth, 5-year CAGR — (26.60%) 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric CNSP LGVN Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 5.86 2.63 4.97
Net debt to EBITDA 0.45 0.20 1.01

Dividend

Metric CNSP LGVN Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric CNSP LGVN Biotechnology median
Market cap 5.86m 5.45m 161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack